CINC - CinCor Pharma says last patient randomized in phase 2 trial for baxdrostat to treat hypertension

• CinCor Pharma ( NASDAQ: CINC ) said the last patient had been randomized in the Phase 2 trial of baxdrostat to treat patients with uncontrolled hypertension.
• The company also said it had an open-label extension study of patients enrolled in the Phase 2 trial, dubbed Halo, with uncontrolled hypertension to evaluate the long-term safety of baxdrostat for up to 52-weeks.
• The company's drug Baxdrostat is designed to selectively reduce aldosterone production, potentially offering a new mechanism that directly targets a key underlying cause of hypertension.
• The company expects to report initial topline data for HALO in the second half of 2022.
• The trial will evaluate safety and efficacy of baxdrostat in subjects taking up to two antihypertensive agents at their maximally tolerated dosages.

For further details see: